Sök artiklar i SveMed+

Observera: SveMed+ upphör att uppdateras!



Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rated version of the UKU Side Effect Rating Scale (UKU-SERS-Pat)
Engelsk titel: Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rated version of the UKU Side Effect Rating Scale (UKU-SERS-Pat) Läs online Författare: Lindström E ; Lewander T ; Malm U ; Malt UF ; Lublin H ; Ahlfors UG Språk: Eng Antal referenser: 9 Dokumenttyp: Artikel UI-nummer: 01123448

Tidskrift

Nordic Journal of Psychiatry 2001;55(suppl 44)5-69 ISSN 0803-9488 E-ISSN 1502-4725 KIBs bestånd av denna tidskrift Denna tidskrift är expertgranskad (Peer-Reviewed)

Sammanfattning

A self-rating version of the UKU Side Effect Rating Scale has been developed. The present study examines the agreement between patients' self-assessment of side effects and the attending clinicians' ratings. The patient sample consisted of 63 patients with schizophrenia under maintenance treatment with risperidone, clozapine or classical antipsychotics. Approximately two thirds of the patients used concomitant medication with e.g. benzodiazepines, SSRIs, anticholinergics. Most inter-correlations between scores for single, corresponding items, subscores of Psychic, Neurological, Autonomic and Other side effects, as well as the Total Score from the patient version of the UKU Side Effect Self Rating Scale (UKU-SERS-Pat) and the clinician version (UKU-SERS-Clin) were found to be statistically significant. Patients reported side effects more frequently and/or rated symptoms more severe than the clinicians. The results support the validity of the SERS-Pat and suggest that patient rated side effects may provide important clinical information not detected by clinician rated interviews. Such information can be utilised both in clinical investigations, in development of treatment programs and for individual patients in clinical practice.